Tango Therapeutics, Inc. (TNGX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 20.30M USD | Liabilities, Current |
| Cash and equivalents | 345.56M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 668.43M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $20.30M | $345.56M | $668.43M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $14.33M | $157.83M | $222.01M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $21.68M | $112.28M | $230.86M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $18.44M | $58.34M | $94.47M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $40.02M | $39.27M | $141.51M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $35.92M | $58.43M | $158.29M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $38.17M | $69.53M | $188.39M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $37.58M | $53.15M | $240.13M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $43.87M | $51.57M | $270.55M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $42.79M | $61.16M | $282.44M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $45.94M | $66.39M | $270.50M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $43.42M | $58.53M | $301.35M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $53.63M | $66.05M | $244.60M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $53.67M | $57.25M | $276.39M | (m) | (m) | (m) |
| 2022-12-31 | $368.13M | $55.55M | $59.97M | $306.17M | $2.00M | (m) | 6.63× |
| 2022-09-30 | $395.29M | $51.32M | $100.31M | $292.98M | $2.00M | (m) | 7.70× |
| 2022-06-30 | $418.36M | $44.68M | $104.58M | $311.77M | $2.00M | (m) | 9.36× |
| 2022-03-31 | $451.88M | $39.21M | $99.91M | $349.98M | $2.00M | (m) | 11.52× |
| 2021-12-31 | $487.25M | $40.69M | $142.75M | $342.51M | $2.00M | (m) | 11.97× |
| 2021-09-30 | $511.81M | $41.99M | $204.97M | $298.83M | $8.00M | (m) | 12.19× |
| 2021-06-30 | (m) | $355.21K | $582.94K | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $301.96K | $1.26M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $114.35K | $1.31M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $115.05K | $1.55M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $24.99K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |